Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
Latest Information Update: 19 Jun 2023
At a glance
- Drugs Fulvestrant (Primary) ; Enzalutamide
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 22 Feb 2022 Planned End Date changed from 1 Dec 2023 to 1 Feb 2027.
- 24 Jan 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 24 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 30 Jun 2022.